Cbpe Capital takes majority stake in Veincentre
Context
CBPE Capital has completed a majority investment in Veincentre, acquiring the stake previously held by Palatine Private Equity alongside the company,s founders. This transaction marks a secondary LBO for the specialist clinic group, which saw significant growth under Palatine,s three-year ownership, including the expansion from 7 to 22 clinics. The deal was structured to support the current management team, led by CEO Maurice McLoughlin, in the next phase of their national expansion strategy. The rationale for the acquisition is rooted in the high demand for specialized outpatient vascular services in the UK and Veincentre,s proven, scalable clinical model. CBPE intends to leverage its extensive experience in multi-site healthcare to further increase the group's clinic density across the UK. The operation was supported by a debt advisory from FRP Advisory and commercial due diligence from Candesic.
Veincentre, which reported an EBITDA margin of [members only] in 2022, is valued in this transaction at an EV/EBITDA multiple of [members only].
-> Deep-dive in Healthcare & Pharma market trends
Target
Veincentre is the United Kingdom,s leading specialist provider of minimally invasive treatments for venous insufficiency, primarily focusing on the treatment of varicose veins and venous ulcers. The company operates a high-efficiency business model centered on outpatient procedures performed under local anesthetic, allowing patients to undergo complex vascular treatments with rapid recovery times. Its value proposition is built on clinical excellence, utilizing a dedicated team of consultant vascular surgeons and interventional radiologists to provide specialized care across a growing national network of clinics. Veincentre,s strategy focuses on increasing patient access to high-quality vascular services that are often underserved by traditional healthcare systems. By concentrating exclusively on venous reflux disorders, the group achieves significant operational expertise and high patient satisfaction ratings. The company serves a large addressable market, as venous conditions affect millions of people in the UK, and it continues to expand its geographic footprint to maintain its position as the premier dedicated venous clinical group in the country.
Ent. Value
[members only]
Equity Value
[members only]
Multiples
EV / Revenue
[members only]
EV / EBITDA
[members only]
EV / EBIT
[members only]
Historical Financials (GBP)
Other operations with Cbpe Capital
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 09/2013 | CBPE CAPITAL | CÔTE RESTAURANTS | UNITED KINGDOM | Restaurants / Chains |
Similar deals in Health Providers
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 06/2023 | LEVINE LEICHTMAN CAPITAL PARTNERS | SEV LASER | UNITED STATES | Aesthetic & Cosmetic Clinics |
| 11/2022 | RADNET | HEART & LUNG IMAGING | UNITED KINGDOM | Radiology |
| 09/2022 | ORADIANSE | REVEL | FRANCE | Radiology |
| 09/2022 | EURAZEO | IMAPOLE | FRANCE | Radiology |
| 08/2022 | FREEMAN SPOGLI | EVERVET PARTNERS | UNITED STATES | Vet Clinics |
| 07/2022 | ANDERA PARTNERS | GROUPE RESONANCE IMAGERIE | FRANCE | Radiology |
| 07/2022 | LATOUR CAPITAL | PHARMACIE LAFAYETTE - GROUPE HYGIE31 | FRANCE | Pharmacy |
| 07/2022 | INFRAVIA CAPITAL | UNIVET | FRANCE | Vet Clinics |
| 06/2022 | EURAZEO | SEVETYS | FRANCE | Vet Clinics |
| 06/2022 | TRITON PARTNERS | ESPERI CARE | FINLAND | Nursing Homes |
REFERENCES
Revenue range: REV 1m GBP - 100m GBP
EBITDA range: £5–25M
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Veincentre by Cbpe Capital are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Target: veincentre
FAQ
What transaction does this page cover?
What was Veincentre’s EBITDA at the time of the deal?
What sources support the information on this transaction?
What is mynth?